Cognition Therapeutics, Inc. (CGTX) Dividend History

Company News

• Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

  Cognition Therapeutics reported positive results from its Phase 2 studies of zervimesine (CT1812) in dementia with Lewy bodies (DLB) and Alzheimer's disease. The company plans to advance zervimesine into late-stage trials for these indications.

  GlobeNewswire Inc.
• Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

  The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Blue Star Foods The Trade: Blue Star Foods Corp. (NASDAQ: BSFC) Director Nubar Herian acquired a total of 219,611 shares an average price of $0.14. To acquire these shares, it cost ...

  Benzinga

  Featured Companies: EKSO
• Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?

  Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

  Zacks Investment Research
• 3 Companies That Went Public Last Month

  Are these IPOs right for you?

  The Motley Fool

  Featured Companies: GTLB PTLO